Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study

J Drugs Dermatol. 2011 Jun;10(6):586-90.


Although there are few differences in the incidence and pathophysiology of acne across various races and ethnicities, there is some evidence that black patients may have larger sebaceous glands and increased sebum production. Of greater clinical relevance, patients with darker skin types are at increased risk for the development of post-inflammatory hyperpigmentation (PIH), which some find as or more troubling than acne itself. This common and bothersome sequelum of acne can be difficult to manage in this population. Topical azelaic acid gel is recognized to have anti-tyrosinase activity, suggesting it may be a suitable treatment option for mild-to-moderate acne with associated moderate-to-severe PIH. This pilot study demonstrates the efficacy of topical AzA gel 15% when applied twice daily for the reduction of both acne and PIH. J

Publication types

  • Clinical Trial

MeSH terms

  • Acne Vulgaris / drug therapy*
  • Acne Vulgaris / pathology
  • Administration, Cutaneous
  • Black People
  • Dermatologic Agents / administration & dosage
  • Dermatologic Agents / adverse effects
  • Dermatologic Agents / therapeutic use*
  • Dicarboxylic Acids / administration & dosage
  • Dicarboxylic Acids / adverse effects
  • Dicarboxylic Acids / therapeutic use*
  • Female
  • Gels
  • Humans
  • Hyperpigmentation / drug therapy*
  • Hyperpigmentation / etiology
  • Inflammation / complications
  • Inflammation / pathology
  • Male
  • Monophenol Monooxygenase / antagonists & inhibitors
  • Pilot Projects
  • Severity of Illness Index
  • Skin Pigmentation
  • Treatment Outcome
  • Young Adult


  • Dermatologic Agents
  • Dicarboxylic Acids
  • Gels
  • Monophenol Monooxygenase
  • azelaic acid